151 related articles for article (PubMed ID: 29178960)
1. The impact of a physician detailing and sampling program for generic atorvastatin: an interrupted time series analysis.
Worthington HC; Cheng L; Majumdar SR; Morgan SG; Raymond CB; Soumerai SB; Law MR
Implement Sci; 2017 Nov; 12(1):141. PubMed ID: 29178960
[TBL] [Abstract][Full Text] [Related]
2. Do newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications.
Kwon HY; Godman B
BMC Health Serv Res; 2016 Apr; 16():130. PubMed ID: 27080530
[TBL] [Abstract][Full Text] [Related]
3. Potential impact of blood cholesterol guidelines on statin treatment in the U.S. population using interrupted time series analysis.
Yew PY; Loth M; Adam TJ; Wolfson J; Liang Y; Tonellato PJ; Chi CL
BMC Cardiovasc Disord; 2024 May; 24(1):245. PubMed ID: 38730371
[TBL] [Abstract][Full Text] [Related]
4. Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy.
Simoens S; Sinnaeve PR
Cardiovasc Drugs Ther; 2013 Feb; 27(1):49-60. PubMed ID: 23242669
[TBL] [Abstract][Full Text] [Related]
5. Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis.
Minard LV; Corkum A; Sketris I; Fisher J; Zhang Y; Saleh A
PLoS One; 2016; 11(7):e0158608. PubMed ID: 27434392
[TBL] [Abstract][Full Text] [Related]
6. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
[TBL] [Abstract][Full Text] [Related]
7. Addition of generic medication vouchers to a pharmacist academic detailing program: effects on the generic dispensing ratio in a physician-hospital organization.
Bhargava V; Greg ME; Shields MC
J Manag Care Pharm; 2010; 16(6):384-92. PubMed ID: 20635829
[TBL] [Abstract][Full Text] [Related]
8. Effects of Physician-directed Pharmaceutical Promotion on Prescription Behaviors: Longitudinal Evidence.
Datta A; Dave D
Health Econ; 2017 Apr; 26(4):450-468. PubMed ID: 26893065
[TBL] [Abstract][Full Text] [Related]
9. Association Between Academic Medical Center Pharmaceutical Detailing Policies and Physician Prescribing.
Larkin I; Ang D; Steinhart J; Chao M; Patterson M; Sah S; Wu T; Schoenbaum M; Hutchins D; Brennan T; Loewenstein G
JAMA; 2017 May; 317(17):1785-1795. PubMed ID: 28464141
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
11. A population-based study of the use of selective serotonin reuptake inhibitors before and after introduction of generic equivalents.
Bolton JM; Dahl M; Sareen J; Enns MW; Leslie WD; Collins DM; Alessi-Severini S
Can J Psychiatry; 2012 Apr; 57(4):223-9. PubMed ID: 22480587
[TBL] [Abstract][Full Text] [Related]
12. Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study.
Hartz I; Sakshaug S; Furu K; Engeland A; Eggen AE; Njølstad I; Skurtveit S
BMC Clin Pharmacol; 2007 Dec; 7():14. PubMed ID: 18053228
[TBL] [Abstract][Full Text] [Related]
13. Patterns of statin utilisation for new users and market dynamics in South Korea: a 13-year retrospective cohort study.
Son KB; Bae S
BMJ Open; 2019 Mar; 9(3):e026603. PubMed ID: 30842117
[TBL] [Abstract][Full Text] [Related]
14. Effect of Attending Practice Style on Generic Medication Prescribing by Residents in the Clinic Setting: An Observational Study.
Ryskina KL; Dine CJ; Kim EJ; Bishop TF; Epstein AJ
J Gen Intern Med; 2015 Sep; 30(9):1286-93. PubMed ID: 26173522
[TBL] [Abstract][Full Text] [Related]
15. Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study.
Geleedst-De Vooght M; Maitland-van der Zee AH; Schalekamp T; Mantel-Teeuwisse A; Jansen P
Drugs Aging; 2010 Jul; 27(7):589-96. PubMed ID: 20583852
[TBL] [Abstract][Full Text] [Related]
16. Generic and therapeutic statin switches and disruptions in therapy.
Chapman RH; Benner JS; Girase P; Benigno M; Axelsen K; Liu LZ; Nichol MB
Curr Med Res Opin; 2009 May; 25(5):1247-60. PubMed ID: 19344292
[TBL] [Abstract][Full Text] [Related]
17. Clinical equivalence of proprietary and generic atorvastatin in lipid clinic patients.
Rahalkar AR; Ban MR; Hegele RA
Can J Cardiol; 2013 Apr; 29(4):418-22. PubMed ID: 22840301
[TBL] [Abstract][Full Text] [Related]
18. Determinants of generic drug substitution in Switzerland.
Decollogny A; Eggli Y; Halfon P; Lufkin TM
BMC Health Serv Res; 2011 Jan; 11():17. PubMed ID: 21269426
[TBL] [Abstract][Full Text] [Related]
19. Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland.
Halava H; Helin-Salmivaara A; Junnila J; Huupponen R
Eur J Clin Pharmacol; 2009 Sep; 65(9):927-33. PubMed ID: 19471912
[TBL] [Abstract][Full Text] [Related]
20. Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.
Romanelli RJ; Segal JB
J Gen Intern Med; 2014 Oct; 29(10):1372-8. PubMed ID: 24957381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
